Viewing data from:

DESVENLAFAXINE SUCCINATE

ANDA

DESVENLAFAXINE SUCCINATE | A204083 | HIKMA PHARMACEUTICALS USA INC

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: PRISTIQ(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 5 NDCs

Highest NADAC/Unit

$0.4459

per ea

Lowest NADAC/Unit

$0.4205

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00054060313DESVENLAFAXINE SUCCNT ER 25 MG	$0.4459	EA	Generic	—	2026-06-17
00054040013DESVENLAFAXINE SUCCNT ER 50 MG	$0.4248	EA	Generic	—	2026-06-17
00054040022DESVENLAFAXINE SUCCNT ER 50 MG	$0.4248	EA	Generic	—	2026-06-17
00054040113DESVENLAFAXINE SUCCNT ER 100 MG	$0.4205	EA	Generic	—	2026-06-17
00054040122DESVENLAFAXINE SUCCNT ER 100 MG	$0.4205	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 5 NDCs (5 FSS)

Lowest Price

$28.47

Highest Price

$93.70

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00054-0401-13DESVENLAFAXINE (EQV-PRISTIQ) 100MG TAB,SA	$28.47	FSS	Golden State Medical Supply, Inc.	06/14/2028
00054-0401-22DESVENLAFAXINE (EQV-PRISTIQ) 100MG TAB,SA	$93.40	FSS	Golden State Medical Supply, Inc.	06/14/2028
00054-0400-13DESVENLAFAXINE (EQV-PRISTIQ) 50MG TAB,SA	$28.47	FSS	Golden State Medical Supply, Inc.	06/14/2028
00054-0400-22DESVENLAFAXINE (EQV-PRISTIQ) 50MG TAB,SA	$93.70	FSS	Golden State Medical Supply, Inc.	06/14/2028
00054-0603-13DESVENLAFAXINE (EQV-PRISTIQ) 25MG TAB,SA	$28.47	FSS	Golden State Medical Supply, Inc.	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain20 active DMFs1 inactive

19 active API suppliers hold Drug Master Files for this ingredient.

ZYDUS LIFESCIENCES LTDDESVENLAFAXINE SUCCINATE USP

DMF 254472012

WOCKHARDT LTDDESVENLAFAXINE SUCCINATE MONOHYDRATE

DMF 256562012

TAPI NL BVDESVENLAFAXINE SUCCINATE

DMF 257492012

LUPIN MANUFACTURING SOLUTIONS LTDDESVENLAFAXINE SUCCINATE

DMF 257512012

APOTEX INCDESVENLAFAXINE SUCCINATE MONOHYDRATE

DMF 257772012

MSN LIFE SCIENCES PRIVATE LTDDESVENLAFAXINE SUCCINATE MONOHYDRATE USP (FORM-1)

DMF 304372016

MACLEODS PHARMACEUTICALS LTDDESVENLAFAXINE SUCCINATE

DMF 309822017

MSN LIFE SCIENCES PRIVATE LTDDESVENLAFAXINE SUCCINATE MONOHYDRATE USP (FORM-II) [ROUTE CODE "SL"]

DMF 311572016

AURORE LIFE SCIENCES PRIVATE LTDDESVENLAFAXINE SUCCINATE USP

DMF 344292019

AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD)DESVENLAFAXINE SUCCINATE MONOHYDRATE

DMF 370362022

HUBEI HAOSUN PHARMACEUTICAL CO LTDDESVENLAFAXINE SUCCINATE

DMF 372372022

HIKAL LTDDESVENLAFAXINE SUCCINATE USP

DMF 374262022

ATUL BIOSCIENCE LTDDESVENLAFAXINE SUCCINATE USP

DMF 375712022

AMI LIFESCIENCES PRIVATE LTDDESVENLAFAXINE SUCCINATE

DMF 380662023

HETERO DRUGS LTDDESVENLAFAXINE SUCCINATE

DMF 385512023

ZHEJIANG APELOA JIAYUAN PHARMACEUTICAL CO LTDDESVENLAFAXINE SUCCINATE

DMF 386242023

MEGAFINE PHARMA P LTDDESVENLAFAXINE SUCCINATE MONOHYDRATE USP (NON-STERILE DRUG SUBSTANCE)

DMF 408392025

COHANCE LIFESCIENCES LTDDESVENLAFAXINE SUCCINATE

DMF 408462024

SNJ LABS PVT LTDDESVENLAFAXINE SUCCINATE USP

DMF 426392025

APITORIA PHARMA PRIVATE LIMITEDDESVENLAFAXINE SUCCINATE USP

DMF 438972026

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveDESVENLAFAXINE SUCCINATE HPMC PRELIMINARY MIX

DMF 257472012

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Feb 18, 2016	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — EQ 100MG BASE

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 16, 2016

No patent or exclusivity listings for this strength.

#002 — EQ 25MG BASE

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 16, 2016

#003 — EQ 50MG BASE

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 16, 2016